1
|
Hey P, Hoermann R, Sinclair M, Chapman B, Testro A, Apostolov R, Angus P, Gow P. Branched-chain amino acid supplementation does not improve measures of sarcopenia in cirrhosis: results of a randomised controlled trial. Aliment Pharmacol Ther 2024; 59:941-952. [PMID: 38404263 DOI: 10.1111/apt.17917] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 11/08/2023] [Accepted: 02/11/2024] [Indexed: 02/27/2024]
Abstract
BACKGROUND Sarcopenia is associated with adverse outcomes in cirrhosis. Branched-chain amino acids (BCAA) target several pathways that lead to muscle loss in this population. AIMS We aimed to evaluate the impact of BCAA supplementation on sarcopenia measures in patients with cirrhosis. METHODS We conducted a 12-month double-blinded, randomised, controlled trial of BCAA supplementation (30 g daily) compared to an equicaloric, equi-nitrogenous whey protein in volunteers with cirrhosis and reduced muscle strength. The primary endpoint was an increase in grip strength and upper limb lean mass measured on DEXA. Mean-adjusted differences (MAD, 95% CI) between groups at 6 and 12 months are reported as treatment effect using a linear mixed model for repeated measures. RESULTS A total of 150 volunteers entered the trial (74 BCAA, 76 control), with a median age of 58 years [IQR 48; 63] and MELD of 14 [12; 17]. At 12 months, 57% in the BCAA arm and 61% in the control arm met the primary endpoint (p = 0.80). No significant between-group difference was found in grip strength (MAD -0.15 kg [-0.37; 0.06], p = 0.29) or upper limb lean mass (1.7 kg [-0.2; 3.6], p = 0.22) at 12 months. No significant differences in other body composition parameters, physical performance, frailty, rates of hospitalisation or mortality were found between the BCAA and the control group. Fatigue improved across the entire cohort, without significant between-group differences. 15% of volunteers reported side effects, with distaste higher in the BCAA arm (p = 0.045). CONCLUSION BCAA supplementation did not improve measures of muscle strength, mass or performance or physical frailty compared to a whey protein supplement in a randomised controlled setting. ACTRN12618000802202.
Collapse
Affiliation(s)
- Penelope Hey
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| | - Rudolf Hoermann
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
| | - Marie Sinclair
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| | - Brooke Chapman
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Nutrition and Dietetics, Austin Health, Heidelberg, Victoria, Australia
| | - Adam Testro
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| | - Ross Apostolov
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| | - Peter Angus
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| | - Paul Gow
- Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia
- Department of Gastroenterology, Austin Health, Heidelberg, Victoria, Australia
| |
Collapse
|
2
|
Apostolov R, Wong D, Low E, Vaz K, Spurio J, Worland T, Liu D, Chan RK, Gow P, Grossmann M, Sinclair M. Testosterone is lower in men with non-alcoholic fatty liver disease and alcohol-related cirrhosis and is associated with adverse clinical outcomes. Scand J Gastroenterol 2023; 58:1328-1334. [PMID: 37282344 DOI: 10.1080/00365521.2023.2220857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/06/2023] [Revised: 05/16/2023] [Accepted: 05/29/2023] [Indexed: 06/08/2023]
Abstract
BACKGROUND/AIMS Low serum testosterone is common in cirrhotic men, but the impact of disease aetiology remains uncertain. This study compares serum total testosterone (TT) levels by disease aetiology and assesses its prognostic value. METHODS Single-centre retrospective study of cirrhotic men who had TT levels measured between 2002 and 2020. A cut-off of 12 nmol/L was used to define low TT and 230 pmol/L for calculated free testosterone (cFT). Linear and logistic regression used to adjust for variables known to affect testosterone levels and assess for an association between levels and outcomes. RESULTS Of 766 cirrhotic men, 33.3% had alcohol-related liver disease (ALD) and 11.9% had non-alcoholic fatty liver disease (NAFLD). The median age was 56 years (interquartile range (IQR) 50-61), and the model for end-stage liver disease (MELD) score 14 (IQR 9-20). TT levels were low in 53.3% of patients, (median 11.0 nmol/L; IQR 3.7-19.8) and cFT low in 79.6% (median 122 pmol/L; IQR 48.6-212). Median TT was lower in men with ALD (7.6 nmol/L; IQR 2.1-16.2) and NAFLD (9.8 nmol/L; IQR 2.75-15.6) compared to other aetiologies (11.0 nmol/L; IQR 3.73-19.8) (p < 0.001 for all), which remained true after adjustment for age and MELD score. TT was inversely associated with 12-month mortality or transplant (381 events, p = 0.02) and liver decompensation (345 events, p = 0.004). CONCLUSIONS Low serum testosterone is common in cirrhotic men and is associated with adverse clinical outcomes. TT levels are significantly lower in ALD and NAFLD compared to other disease aetiologies. Further large-scale studies are required to assess the potential benefits of testosterone therapy.
Collapse
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| | - Darren Wong
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| | - Elizabeth Low
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
| | - Karl Vaz
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
| | - Jessica Spurio
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
| | - Thomas Worland
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
| | - Dorothy Liu
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
| | | | - Paul Gow
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| | - Mathis Grossmann
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
- Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia
| | - Marie Sinclair
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
3
|
Hey P, Hoermann R, Gow P, Hanrahan TP, Testro AG, Apostolov R, Sinclair M. Reduced upper limb lean mass on dual energy X-ray absorptiometry predicts adverse outcomes in male liver transplant recipients. World J Transplant 2022; 12:120-130. [PMID: 35979539 PMCID: PMC9258268 DOI: 10.5500/wjt.v12.i6.120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 04/24/2022] [Accepted: 05/23/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Pre-transplant muscle wasting measured by computed tomography has been associated with adverse clinical outcomes after liver transplantation including increased rates of sepsis and hospitalisation days. Upper limb lean mass (LM) measured by dual-energy X-ray absorptiometry (DEXA) was recently identified as a novel predictor of sarcopenia-associated mortality in men waitlisted for transplantation.
AIM To investigate the use of DEXA LM in predicting gender-stratified early post-transplant outcomes.
METHODS Liver transplant recipients who underwent pre-transplant DEXA body composition imaging between 2002 and 2017 were included. Endpoints included post-transplant mortality and graft failure, bacterial infections, acute cellular rejection (ACR) and intensive care and total hospital length of stay.
RESULTS Four hundred and sixty-nine patients met inclusion criteria of which 338 were male (72%). Median age was 55.0 years (interquartile range 47.4, 59.7) and model for end-stage liver disease (MELD) score 16. Median time from assessment to transplantation was 7 mo (3.5, 12). Upper limb LM was inversely associated with bacterial infections at 180 d post-transplant (hazard ratio = 0.42; 95% confidence interval: 0.20-0.89; P = 0.024) in males only. There was a negative correlation between upper limb LM and intensive care (τb = -0.090, P = 0.015) and total hospital length of stay (τb = -0.10, P = 0.0078) in men. In women, neither MELD nor body composition parameters were associated with post-transplant adverse outcomes or increased length of stay. Body composition parameters, MELD and age were not associated with 90-d mortality or graft failure in either gender. There were no significant predictors of early ACR.
CONCLUSION Sarcopenia is an independent and potentially modifiable predictor of increased post-transplant bacterial infections and hospital length of stay in men with cirrhosis. DEXA upper limb LM provides a novel measure of muscle wasting that has prognostic value in this cohort. The lack of association in women requires further investigation.
Collapse
Affiliation(s)
- Penelope Hey
- Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| | - Rudolf Hoermann
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| | - Paul Gow
- Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| | | | - Adam G Testro
- Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| | - Ross Apostolov
- Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| | - Marie Sinclair
- Liver Transplant Unit, Austin Health, Heidelberg 3084, Australia
- Department of Medicine, University of Melbourne, Melbourne 3052, Australia
| |
Collapse
|
4
|
Apostolov R, Gianatti E, Wong D, Kutaiba N, Gow P, Grossmann M, Sinclair M. Testosterone therapy reduces hepatic steatosis in men with type 2 diabetes and low serum testosterone concentrations. World J Hepatol 2022; 14:754-765. [PMID: 35646271 PMCID: PMC9099110 DOI: 10.4254/wjh.v14.i4.754] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/24/2021] [Revised: 11/17/2021] [Accepted: 04/04/2022] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in people with diabetes with no available treatment.
AIM To explore the effect of testosterone treatment on liver. Testosterone therapy improves insulin resistance and reduces total body fat, but its impact on the liver remains poorly studied.
METHODS This secondary analysis of a 40 wk, randomised, double-blinded, placebo-controlled trial of intramuscular testosterone undecanoate in men with type 2 diabetes and lowered serum testosterone concentrations evaluated the change in hepatic steatosis as measured by liver fat fraction on magnetic resonance imaging (MRI).
RESULTS Of 88 patients enrolled in the index study, 39 had liver MRIs of whom 20 received testosterone therapy and 19 received placebo. All patients had > 5% hepatic steatosis at baseline and 38 of 39 patients met diagnostic criteria for NAFLD. Median liver fat at baseline was 15.0% (IQR 11.5%-21.1%) in the testosterone and 18.4% (15.0%-28.9%) in the placebo group. Median ALT was 34units/L (26-38) in the testosterone and 32units/L (25-52) in the placebo group. At week 40, patients receiving testosterone had a median reduction in absolute liver fat of 3.5% (IQR 2.9%-6.4%) compared with an increase of 1.2% in the placebo arm (between-group difference 4.7% P < 0.001). After controlling for baseline liver fat, testosterone therapy was associated with a relative reduction in liver fat of 38.3% (95% confidence interval 25.4%-49.0%, P < 0.001).
CONCLUSION Testosterone therapy was associated with a reduction in hepatic steatosis in men with diabetes and low serum testosterone. Future randomised studies of testosterone therapy in men with NAFLD focusing on liver-related endpoints are therefore justified.
Collapse
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, VIC, Australia
- Department of Medicine, University of Melbourne, Parkville 3010, VIC, Australia
| | - Emily Gianatti
- Department of Endocrinology, Fiona Stanley Hospital, Murdoch 6150, WA, Australia
| | - Darren Wong
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, VIC, Australia
| | - Numan Kutaiba
- Department of Radiology, Austin Health, Heidelberg 3084, VIC, Australia
| | - Paul Gow
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, VIC, Australia
- Department of Medicine, University of Melbourne, Parkville 3010, VIC, Australia
| | - Mathis Grossmann
- Department of Medicine, University of Melbourne, Parkville 3010, VIC, Australia
- Department of Endocrinology, Austin Health, Heidelberg 3084, VIC, Australia
| | - Marie Sinclair
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, VIC, Australia
- Department of Medicine, University of Melbourne, Parkville 3010, VIC, Australia
| |
Collapse
|
5
|
Be KH, Zorron Cheng Tao Pu L, Apostolov R, Vaughan R, Efthymiou M, Chandran S. Gastrointestinal: Gastric variceal coil migration: A rare entity in endoscopy. J Gastroenterol Hepatol 2022; 37:281. [PMID: 34378232 DOI: 10.1111/jgh.15637] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/16/2021] [Revised: 07/12/2021] [Accepted: 07/22/2021] [Indexed: 12/09/2022]
Affiliation(s)
- K H Be
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia
| | - L Zorron Cheng Tao Pu
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia
| | - R Apostolov
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
| | - R Vaughan
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
| | - M Efthymiou
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
| | - S Chandran
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Victoria, Australia.,Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
6
|
Low ESL, Apostolov R, Wong D, Lin S, Kutaiba N, Grace JA, Sinclair M. Hepatocellular carcinoma surveillance and quantile regression for determinants of underutilisation in at-risk Australian patients. World J Gastrointest Oncol 2021; 13:2149-2160. [PMID: 35070048 PMCID: PMC8713329 DOI: 10.4251/wjgo.v13.i12.2149] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/16/2021] [Revised: 07/13/2021] [Accepted: 09/19/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND While clinical guidelines recommend hepatocellular carcinoma (HCC) surveillance for at-risk individuals, reported surveillance rates in the United States and Europe remain disappointingly low.
AIM To quantify HCC surveillance in an Australian cohort, and assess for factors associated with surveillance underutilisation.
METHODS All patients undergoing HCC surveillance liver ultrasounds between January 1, 2018 to June 30, 2018 at a tertiary hospital in Melbourne, Australia, were followed until July 31, 2020, or when surveillance was no longer required. The primary outcome was the percentage of time up-to-date with HCC surveillance (PTUDS). Quantile regression was performed to determine the impact of factors associated with HCC surveillance underutilisation.
RESULTS Among 775 at-risk patients followed up for a median of 27.5 months, the median PTUDS was 84.2% (IQR: 66.3%-96.3%). 85.0% of patients were followed up by specialist gastroenterologists. Amongst those receiving specialist care, quantile regression demonstrated differential associations at various quantile levels of PTUDS for several factors. Older age at the 25th quantile (estimate 0.002 per percent, P = 0.03), and cirrhotic status at the 75th quantile (estimate 0.021, P = 0.017), were significantly associated with greater percentage of time up-to-date. African ethnicity (estimate -0.089, P = 0.048) and a culturally and linguistically diverse (CALD) background (estimate -0.063, P = 0.01) were significantly associated with lower PTUDS at the 50th quantile, and again for CALD at the 75th quantile (estimate -0.026, P = 0.045).
CONCLUSION While median PTUDS in this Australian cohort study was 84.2%, awareness of the impact of specific factors across PTUDS quantiles can aid targeted interventions towards improved HCC surveillance.
Collapse
Affiliation(s)
- Elizabeth SL Low
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Ross Apostolov
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne 3000, Victoria, Australia
| | - Darren Wong
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Sandra Lin
- Department of Radiology, Monash Health, Clayton 3168, Victoria, Australia
| | - Numan Kutaiba
- Department of Radiology, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Josephine A Grace
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne 3000, Victoria, Australia
| | - Marie Sinclair
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- Department of Medicine, University of Melbourne, Melbourne 3000, Victoria, Australia
| |
Collapse
|
7
|
Pham AD, Vaz K, Ardalan ZS, Sinclair M, Apostolov R, Gardner S, Majeed A, Mishra G, Kam NM, Patwala K, Kutaiba N, Arachchi N, Bell S, Dev AT, Lubel JS, Nicoll AJ, Sood S, Kemp W, Roberts SK, Fink M, Testro AG, Angus PW, Gow PJ. Clinical outcomes of patients with two small hepatocellular carcinomas. World J Hepatol 2021; 13:1439-1449. [PMID: 34786178 PMCID: PMC8568581 DOI: 10.4254/wjh.v13.i10.1439] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/25/2021] [Revised: 06/28/2021] [Accepted: 09/02/2021] [Indexed: 02/06/2023] Open
Abstract
BACKGROUND Management of single small hepatocellular carcinoma (HCC) is straightforward with curative outcomes achieved by locoregional therapy or resection. Liver transplantation is often considered for multiple small or single large HCC. Management of two small HCC whether presenting synchronously or sequentially is less clear.
AIM To define the outcomes of patients presenting with two small HCC.
METHODS Retrospective review of HCC databases from multiple institutions of patients with either two synchronous or sequential HCC ≤ 3 cm between January 2000 and March 2018. Primary outcomes were overall survival (OS) and transplant-free survival (TFS).
RESULTS 104 patients were identified (male n = 89). Median age was 63 years (interquartile range 58-67.75) and the most common aetiology of liver disease was hepatitis C (40.4%). 59 (56.7%) had synchronous HCC and 45 (43.3%) had sequential. 36 patients died (34.6%) and 25 were transplanted (24.0%). 1, 3 and 5-year OS was 93.0%, 66.1% and 62.3% and 5-year post-transplant survival was 95.8%. 1, 3 and 5-year TFS was 82.1%, 45.85% and 37.8%. When synchronous and sequential groups were compared, OS (1,3 and 5 year synchronous 91.3%, 63.8%, 61.1%, sequential 95.3%, 69.5%, 64.6%, P = 0.41) was similar but TFS was higher in the sequential group (1,3 and 5 year synchronous 68.5%, 37.3% and 29.7%, sequential 93.2%, 56.6%, 48.5%, P = 0.02) though this difference did not remain during multivariate analysis.
CONCLUSION TFS in patients presenting with two HCC ≤ 3 cm is poor regardless of the timing of the second tumor. All patients presenting with two small HCC should be considered for transplantation.
Collapse
Affiliation(s)
- Anh Duy Pham
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Karl Vaz
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Zaid S Ardalan
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- Department of Gastroenterology, Alfred Health, Melbourne 3000, Victoria, Australia
| | - Marie Sinclair
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| | - Ross Apostolov
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| | - Sarah Gardner
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Ammar Majeed
- Department of Gastroenterology, Alfred Health, Melbourne 3000, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia
| | - Gauri Mishra
- Department of Gastroenterology and Hepatology, Monash Health, Clayton 3168, Victoria, Australia
| | - Ning Mao Kam
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Kurvi Patwala
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
| | - Numan Kutaiba
- Department of Radiology, Austin Health, Heidelberg 3084, Victoria, Australia
- Department of Radiology, Eastern Health, Box Hill 3128, Victoria, Australia
| | - Niranjan Arachchi
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Department of Gastroenterology, Western Health, Footscray 3011, Victoria, Australia
| | - Sally Bell
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
- Department of Gastroenterology and Hepatology, Monash Health, Clayton 3168, Victoria, Australia
| | - Anouk T Dev
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Department of Gastroenterology and Hepatology, Monash Health, Clayton 3168, Victoria, Australia
| | - John S Lubel
- Department of Gastroenterology, Alfred Health, Melbourne 3000, Victoria, Australia
- Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia
| | - Amanda J Nicoll
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Department of Gastroenterology, Eastern Health, Box Hill 3128, Victoria, Australia
| | - Siddharth Sood
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
- Department of Gastroenterology, Royal Melbourne Hospital, Parkville 3050, Victoria, Australia
| | - William Kemp
- Department of Gastroenterology, Alfred Health, Melbourne 3000, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia
| | - Stuart K Roberts
- Department of Gastroenterology, Alfred Health, Melbourne 3000, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- Central Clinical School, Monash University, Melbourne 3004, Victoria, Australia
| | - Michael Fink
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| | - Adam G Testro
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| | - Peter W Angus
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| | - Paul J Gow
- The Victorian Liver Transplant Unit, Austin Health, Heidelberg 3084, Victoria, Australia
- The Melbourne Liver Group, Melbourne 3000, Victoria, Australia
- The University of Melbourne, Parkville 3010, Victoria, Australia
| |
Collapse
|
8
|
Abstract
Our article presents a case of Herpes Simplex esophagitis in an immunocompromised patient who presented with severe odynophagia on a background of Metastatic Merkel Cell Carcinoma. Our patient's clinical history and examination findings initially suggest a likely fungal etiology for esophagitis, however as the case develops the diagnosis of Herpes Simplex esophagitis becomes more evident. Our case highlights common endoscopic and histological abnormalities seen in Herpes Simplex esophagitis. Our discussion elaborates on these abnormalities and reminds readers of the treatment for HSV esophagitis.
Collapse
Affiliation(s)
- Nadia Saliba
- Department of Gastroenterology, Eastern Health, Box Hill Hospital, Victoria, Australia.
| | - Minnie Au
- Department of Gastroenterology, Eastern Health, Box Hill Hospital, Victoria, Australia
| | - Ross Apostolov
- Department of Gastroenterology, Eastern Health, Box Hill Hospital, Victoria, Australia
| |
Collapse
|
9
|
Tan N, Apostolov R, Au M, Vasudevan A, Nicoll A. Investigating Liver Masses in Young Adults. Am J Med 2021; 134:596-598. [PMID: 33245924 DOI: 10.1016/j.amjmed.2020.10.028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/03/2020] [Revised: 10/16/2020] [Accepted: 10/21/2020] [Indexed: 11/18/2022]
Affiliation(s)
- Natassia Tan
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia.
| | - Ross Apostolov
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia
| | - Minnie Au
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia
| | - Abhinav Vasudevan
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia; Eastern Health Clinical School, Monash University, Victoria, Australia
| | - Amanda Nicoll
- Department of Gastroenterology and Hepatology, Eastern Health, Box Hill, Victoria, Australia; Eastern Health Clinical School, Monash University, Victoria, Australia
| |
Collapse
|
10
|
Chauhan A, Apostolov R, van Langenberg D, Garg M. Faecal microbiota transplantation for recurrent Clostridioides difficile infection: an Australian experience - effective, safe, yet room for improvement. Intern Med J 2021; 51:106-110. [PMID: 33572016 DOI: 10.1111/imj.15162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/01/2020] [Revised: 05/29/2020] [Accepted: 08/31/2020] [Indexed: 11/28/2022]
Abstract
Faecal microbiota transplantation (FMT) is reportedly effective and safe for the management of recurrent or refractory Clostridioides difficile infection (CDI), yet real-world data of outcomes of FMT in Australia are limited. In this series, FMT safely resulted in resolution of CDI in 19 patients with reduced healthcare utilisation after 25 FMT, but one patient was diagnosed with an anti-nuclear antibody-positive constitutional illness and Hashimoto thyroiditis following FMT. Further prospective evaluation of the utility of FMT earlier in CDI treatment algorithms to minimise cost and morbidity, and recipient follow up for immune-mediated conditions, is required.
Collapse
Affiliation(s)
- Ayushi Chauhan
- Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia
| | - Ross Apostolov
- Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia
| | - Daniel van Langenberg
- Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.,Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia
| | - Mayur Garg
- Department of Gastroenterology, Eastern Health, Melbourne, Victoria, Australia.,Eastern Health Clinical School, Monash University, Melbourne, Victoria, Australia.,Department of Gastroenterology and Hepatology, Royal Melbourne Hospital, Melbourne, Victoria, Australia.,Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia
| |
Collapse
|
11
|
Hey P, Gow P, Testro AG, Apostolov R, Chapman B, Sinclair M. Nutraceuticals for the treatment of sarcopenia in chronic liver disease. Clin Nutr ESPEN 2021; 41:13-22. [PMID: 33487256 DOI: 10.1016/j.clnesp.2020.11.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2020] [Accepted: 11/30/2020] [Indexed: 02/07/2023]
Abstract
BACKGROUND AND AIMS Sarcopenia, defined as loss of muscle mass, strength and function, is associated with adverse clinical outcomes in patients with cirrhosis. Despite improved understanding of the multifaceted pathogenesis, there are few established therapies to treat or prevent muscle loss in this population. This narrative review examines the available literature investigating the role of nutraceuticals for the prevention or treatment of muscle wasting in chronic liver disease. METHODS A comprehensive search or Medline and PubMED databases was conducted. Reference lists were screened to identify additional articles. RESULTS A number of nutritional supplements and vitamins target the specific metabolic derangements that contribute to sarcopenia in cirrhosis including altered amino acid metabolism, hyperammonaemia and inflammation. Branched chain amino acid (BCAA) supplementation has proposed anabolic effects through dual pathways of enhanced ammonia clearance and stimulation of muscle protein synthesis. l-carnitine also has multimodal effects on muscle and shows promise as a therapy for muscle loss through anti-inflammatory, antioxidant and ammonia lowering properties. Other nutraceuticals including l-ornithine l-aspartate, omega-3 polyunsaturated fatty acids and zinc and vitamin D supplementation, may similarly have positive effects on muscle homeostasis, however further evidence to support their use in cirrhotic populations is required. CONCLUSION Nutraceuticals offer a promising and likely safe adjunct to standard care for sarcopenia in cirrhosis. While there is most evidence to support the use of BCAA and l-carnitine supplementation, further well-designed clinical trials are needed to elucidate their efficacy as a therapy for muscle loss in this population.
Collapse
Affiliation(s)
- Penelope Hey
- Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia.
| | - Paul Gow
- Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia.
| | - Adam G Testro
- Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia.
| | - Ross Apostolov
- Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia.
| | - Brooke Chapman
- The University of Melbourne, Parkville, Victoria, Australia; Department of Nutrition and Dietetics, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia.
| | - Marie Sinclair
- Liver Transplant Unit, Austin Health, 145 Studley Rd, Heidelberg, Victoria, Australia; The University of Melbourne, Parkville, Victoria, Australia.
| |
Collapse
|
12
|
Au M, Walcott J, Apostolov R, Lewis D, Hassen AS. Oesophageal rupture presenting as upper gastrointestinal bleed. N Z Med J 2020; 133:106-109. [PMID: 33032309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Affiliation(s)
- Minnie Au
- Gastroenterology, Eastern Health, Australia
| | - James Walcott
- Upper Gastrointestinal Surgery, Eastern Health, Australia
| | | | | | | |
Collapse
|
13
|
Vasudevan A, Parthasarathy N, Con D, Nicolaides S, Apostolov R, Chauhan A, Bishara M, Luber RP, Joshi N, Wan A, Rickard JA, Long T, Connoley D, Sparrow MP, Gibson PR, van Langenberg DR. Thiopurines vs methotrexate: Comparing tolerability and discontinuation rates in the treatment of inflammatory bowel disease. Aliment Pharmacol Ther 2020; 52:1174-1184. [PMID: 32794599 DOI: 10.1111/apt.16039] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 05/17/2020] [Accepted: 07/23/2020] [Indexed: 12/14/2022]
Abstract
BACKGROUND There are safety concerns regarding immunomodulators (thiopurines and methotrexate) for treatment of inflammatory bowel disease (IBD). AIM To compare the long-term tolerability, and persistence of thiopurine and methotrexate therapy in IBD. METHODS A retrospective cohort study was performed at two hospitals between 1 January 2004 and 31 December 2016 for patients commenced on thiopurines or methotrexate for IBD. Treatment discontinuation rates, intolerances and disease activity were obtained from medical records. RESULTS There were 782 patients commenced on immunomodulator therapy; 244 (31%) on methotrexate with folate (67% subcutaneous therapy) and 538 (69%) on thiopurine (73% azathioprine). Median follow-up was 42 vs 47 months (P = 0.09). In patients on thiopurines, median 6-TGN was 298 pmol/8 x 108 RBCs, while the median dose of methotrexate was 25 mg weekly. Methotrexate recipients had a higher rate of prior immunomodulator intolerance, were typically older and had a longer disease duration (54% vs 3%, median 43 vs 36 years, 6 vs 5 years, respectively, each P < 0.05). Overall, 208 (27%) discontinued therapy due to adverse events, (40% on methotrexate vs 19% on thiopurines, P < 0.001), including nausea (18% vs 4%), fatigue (7% vs 2%) and hepatotoxicity (8% vs 2%, each P < 0.001). Hospitalisations from adverse events (0.8% vs 0.9%) and serious infections (9% vs 12%), and deaths (1% vs 0%) were comparable between groups (all P > 0.05). Discontinuation due to adverse events occurred later in patients on methotrexate than on thiopurines (median 7 vs 5 months, P = 0.08). CONCLUSION Discontinuation of methotrexate occurred at rates twice that of dose-optimised thiopurine therapy.
Collapse
Affiliation(s)
- Abhinav Vasudevan
- Department of Gastroenterology and Hepatology, Monash University, Eastern Health Clinical School, Victoria, Australia
| | - Nina Parthasarathy
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Danny Con
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Steven Nicolaides
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Ross Apostolov
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Ayushi Chauhan
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Maria Bishara
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Raphael P Luber
- Department of Gastroenterology, Alfred Health and Monash University, Victoria, Australia
| | - Neetima Joshi
- Department of Gastroenterology, Alfred Health and Monash University, Victoria, Australia
| | - Anna Wan
- Department of Gastroenterology, Alfred Health and Monash University, Victoria, Australia
| | - James A Rickard
- Department of Gastroenterology and Hepatology, Eastern Health, Victoria, Australia
| | - Tony Long
- Monash University, Eastern Health Clinical School, Victoria, Australia
| | - Declan Connoley
- Monash University, Eastern Health Clinical School, Victoria, Australia
| | - Miles P Sparrow
- Department of Gastroenterology, Alfred Health and Monash University, Victoria, Australia
| | - Peter R Gibson
- Department of Gastroenterology, Alfred Health and Monash University, Victoria, Australia
| | - Daniel R van Langenberg
- Department of Gastroenterology and Hepatology, Monash University, Eastern Health Clinical School, Victoria, Australia
| |
Collapse
|
14
|
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology, Eastern Health, Victoria, Australia.
| | - Natassia Tan
- Department of Gastroenterology, Eastern Health, Victoria, Australia
| | | |
Collapse
|
15
|
Tan N, Apostolov R, Vasudevan A. An Unusual Cause of Duodenal Ulceration. Gastroenterology 2020; 159:e3-e5. [PMID: 32017906 DOI: 10.1053/j.gastro.2020.01.038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/14/2020] [Accepted: 01/20/2020] [Indexed: 12/02/2022]
Affiliation(s)
- Natassia Tan
- Department of Gastroenterology, Eastern Health, Victoria, Australia.
| | - Ross Apostolov
- Department of Gastroenterology, Eastern Health, Victoria, Australia
| | | |
Collapse
|
16
|
Worland T, Apostolov R, Asadi K, Leung C. Hepatitis B virus activity is not associated with degree of liver steatosis in patients with hepatitis B-related chronic liver disease. Liver Int 2020; 40:1500-1502. [PMID: 31883410 DOI: 10.1111/liv.14344] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
BACKGROUND & AIMS The recently published manuscript by Zhu and colleagues "Hepatitis B virus infection and risk of non-alcoholic fatty liver disease: A population-based cohort study" found no correlation between presence of chronic HBV and presence of common risk factors for non-alcoholic fatty liver disease on primary analysis. A limitation to this study, like most population based research, is the absence of liver histology, which is considered gold standard for assessment of non-alcoholic fatty liver disease. METHODS Our group studied the association between hepatitis B viral activity and non-alcoholic fatty liver disease activity as measured by grade of steatohepatitis/fibrosis on liver biopsy by analysing consecutive liver histology samples from patients with chronic hepatitis B at a single quaternary liver transplant centre. RESULTS Linear regression modelling for active viral hepatitis on histological examination against degree of steatohepatitis showed no correlation (r2 = .018, all P> .1). Linear regression of degree of steatohepatitis vs hepatitis B viral load also showed no correlation. CONCLUSIONS Our work is concordant with the manuscript from Zhu et al; we found no significant correlation between hepatitis B viral activity and degree of steatohepatitis.
Collapse
Affiliation(s)
- Thomas Worland
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Vic., Australia
| | - Ross Apostolov
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Vic., Australia
| | - Khashayar Asadi
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Vic., Australia
| | - Christopher Leung
- Department of Gastroenterology and Hepatology, Austin Health, Melbourne, Vic., Australia
| |
Collapse
|
17
|
Apostolov R, Nicolaides S, Vasudevan A. Megacolon Complicating Ulcerative Colitis and Clostridiodes Infection. Am J Med Sci 2020; 360:e1-e2. [PMID: 32448498 DOI: 10.1016/j.amjms.2020.04.040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/06/2020] [Revised: 04/25/2020] [Accepted: 04/30/2020] [Indexed: 11/16/2022]
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology, Eastern Health, Box Hill, Victoria, Australia.
| | - Steven Nicolaides
- Department of Gastroenterology, Eastern Health, Box Hill, Victoria, Australia
| | - Abhinav Vasudevan
- Department of Gastroenterology, Eastern Health, Box Hill, Victoria, Australia
| |
Collapse
|
18
|
Apostolov R, Nicolaides S, Vasudevan A. Complex Fistulizing Crohn's Disease. Gastroenterology 2020; 158:827-828. [PMID: 31738912 DOI: 10.1053/j.gastro.2019.10.041] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Accepted: 10/21/2019] [Indexed: 12/02/2022]
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology, Eastern Health, Victoria, Australia.
| | | | | |
Collapse
|
19
|
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia.
| | - Natassia Tan
- Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia
| | - Abhinav Vasudevan
- Department of Gastroenterology, Eastern Health, Melbourne, VIC, Australia
| |
Collapse
|
20
|
Low ESL, Patwala K, Apostolov R. Dyspnoea, clubbing, cirrhosis, and bubbles in both sides of the heart suggests hepatopulmonary syndrome. Lancet 2019; 394:510. [PMID: 31402029 DOI: 10.1016/s0140-6736(19)31720-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 03/08/2019] [Accepted: 07/04/2019] [Indexed: 10/26/2022]
Affiliation(s)
| | - Kurvi Patwala
- Liver Transplant Unit, Austin Hospital, Heidelberg, VIC, Australia
| | - Ross Apostolov
- Liver Transplant Unit, Austin Hospital, Heidelberg, VIC, Australia
| |
Collapse
|
21
|
Apostolov R, Sinclair M, Lokan J, Angus P. Successful liver transplantation in common variable immune deficiency with reversal of hepatopulmonary syndrome. BMJ Case Rep 2019; 12:12/4/e226095. [PMID: 30948390 DOI: 10.1136/bcr-2018-226095] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
Common variable immune deficiency (CVID) is a primary immunodeficiency disorder that is associated with abnormal liver function tests, however advanced liver disease is uncommon. Hepatopulmonary syndrome (HPS) is a rare but debilitating complication of CVID-associated liver disease. We report a case of CVID complicated by HPS that was successfully treated with orthotopic liver transplant, with the patient recovering to normal hepatic function and successfully weaning off domiciliary oxygen post-transplantation.
Collapse
Affiliation(s)
- Ross Apostolov
- Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
| | - Marie Sinclair
- Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
| | - Julie Lokan
- Department of Pathology, Austin Health, Heidelberg, Victoria, Australia
| | - Peter Angus
- Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
| |
Collapse
|
22
|
Apostolov R, Schelleman A, Gow P. Dilated abdominal veins from Budd-Chiari syndrome and caval obstruction. Lancet Gastroenterol Hepatol 2018; 3:812. [PMID: 30353858 DOI: 10.1016/s2468-1253(18)30302-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/15/2018] [Revised: 08/24/2018] [Accepted: 08/24/2018] [Indexed: 11/16/2022]
Affiliation(s)
- Ross Apostolov
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia.
| | | | - Paul Gow
- Department of Gastroenterology and Liver Transplant Unit, Austin Health, Melbourne, VIC, Australia; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia
| |
Collapse
|
23
|
Vasudevan A, Ardalan ZS, Ahmed N, Apostolov R, Gow PJ, Testro AG, Gane EJ, Angus PW. Long-term safety and efficacy of tenofovir disoproxil fumarate substitution for hepatitis B immunoglobulin following liver transplantation. JGH Open 2018; 2:288-294. [PMID: 30619939 PMCID: PMC6308096 DOI: 10.1002/jgh3.12086] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/17/2018] [Revised: 07/23/2018] [Accepted: 07/27/2018] [Indexed: 01/12/2023]
Abstract
Background and Aims Limitations to the use of long‐term Hepatitis B Immunoglobulin (HBIg) following liver transplantation for hepatitis B (HBV) have led to the substitution of HBIg with oral nucleo(s)tide analogue prophylaxis. We prospectively assessed the long‐term safety and efficacy of switching to tenofovir disoproxil fumarate (TDF) from HBIg. Methods An open‐label, multicenter switch study was conducted to evaluate the substitution of TDF for HBIg whilst continuing lamivudine (LAM) therapy in preventing the recurrence of HBV in patients who had been maintained as hepatitis B surface antigen (HBsAg)‐negative posttransplantation for at least 12 months. Results Eighteen patients were enrolled (median age 66 years, range 42–78 years); 84% were male, and 78% on calcineurin inhibitors. Median time after transplantation was 14 years (range 5–19), and median duration of HBIg/LAM prior to the switch was 10 years (range 1–14). Median follow‐up was 5 years (range 5–8). Of 18 patients, 16 (89%) remained HBsAg and HBV DNA negative at the end of follow‐up. Two patients had re‐emergence of HBsAg without a detectable HBV DNA and no clinical sequelae. Creatinine clearance significantly reduced (median 59 mL/min to 51 mL/min, P = 0.03), necessitating dose reduction of TDF in six (33%) participants, with two eventually ceasing TDF. One patient switched back to HBIg by choice. All patients who changed therapy maintained an undetectable HBsAg. Conclusion Substitution of HBIg with TDF in patients on LAM is well tolerated and effective for the long‐term prevention of HBV recurrence posttransplantation. Renal dysfunction occurs frequently in the posttransplant setting and can require dose adjustment of TDF or change of therapy.
Collapse
Affiliation(s)
| | - Zaid S Ardalan
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| | - Navera Ahmed
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| | - Ross Apostolov
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| | - Paul J Gow
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| | - Adam G Testro
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| | - Ed J Gane
- New Zealand Liver Transplant Unit Auckland City Hospital New Zealand
| | - Peter W Angus
- Liver Transplant Unit Victoria Austin Health Melbourne Australia
| |
Collapse
|
24
|
Srinivasan A, Apostolov R, Leong A, Johnson D. Atraumatic chylous ascites: an unusual presentation of bladder cancer. BMJ Case Rep 2017; 2017:bcr-2016-219006. [PMID: 28473429 DOI: 10.1136/bcr-2016-219006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
We describe a case of bladder cancer presenting with atraumatic chylous ascites, which remains an extremely rare presentation of this condition. A previously well, elderly ex-smoker with no prior history of abdominal surgery was referred for investigation of progressive dyspnoea, increasing peripheral oedema and new-onset ascites, on a background of long-standing alcohol consumption (four standard drinks daily). Liver biochemistry and coagulation profile were normal apart from marked hypoalbuminaemia. Doppler ultrasound of the liver demonstrated normal echotexture and patent vasculature. Abdominal paracentesis yielded 8 L of milk-coloured, triglyceride-rich fluid with abundant malignant cells. Urine cytology demonstrated malignant transitional cells, with radiological evidence of a large enhancing bladder mass, with evidence of adjacent lymphadenopathy and omental involvement. A diagnosis of metastatic stage IV transitional cell bladder cancer was made. The patient declined palliative chemotherapy and passed away 2 months after their initial presentation.
Collapse
Affiliation(s)
| | - Ross Apostolov
- Department of Gastroenterology, Austin Health, Melbourne, Australia
| | - Amanda Leong
- Department of Gastroenterology, Austin Health, Melbourne, Australia
| | - Douglas Johnson
- Department of General Medicine, Austin Health, Heidelberg, Australia
| |
Collapse
|
25
|
Apostolov R, Asadi K, Lokan J, Kam N, Testro A. Mycophenolate mofetil toxicity mimicking acute cellular rejection in a small intestinal transplant. World J Transplant 2017; 7:98-102. [PMID: 28280702 PMCID: PMC5324035 DOI: 10.5500/wjt.v7.i1.98] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/26/2016] [Revised: 12/21/2016] [Accepted: 01/14/2017] [Indexed: 02/05/2023] Open
Abstract
Mycophenolate mofetil (MMF) is an important medication used for maintenance immunosuppression in solid organ transplants. A common gastrointestinal (GI) side effect of MMF is enterocolitis, which has been associated with multiple histological features. There is little data in the literature describing the histological effects of MMF in small intestinal transplant (SIT) recipients. We present a case of MMF toxicity in a SIT recipient, with histological changes in the donor ileum mimicking persistent acute cellular rejection (ACR). Concurrent biopsies of the patient’s native colon showed similar changes to those from the donor small bowel, suggesting a non-graft specific process, raising suspicion for MMF toxicity. The MMF was discontinued and complete resolution of these changes occurred over three weeks. MMF toxicity should therefore be considered as a differential diagnosis for ACR and graft-versus-host disease in SITs.
Collapse
|